Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care. To learn more about Karmanos Cancer Institute clinical trials or to see if a trial is right for you, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment below
  • A Phase 1b/2a Multicenter, Open-label, Dose-escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CC-220 As Monotherapy and in Combination with Other Treatments in Subjects with Multiple

    Cancer Categories
    • Hematologic (Blood Cancers)
    Karmanos Trial ID
    • 2016-086
    NCT ID
    • NCT02773030
    Age Group
    • Adult
    • National
    PhaseClick for Clinical Trial Phase DefinitionPhase I
    Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
    • Phase I/II
    Principal Investigator
    • Jeffrey
      Zonder, M.D.

      Oncology - Hematology, Oncology - Medical View Profile


    The primary objective of the study is to determine the maximum tolerated doses (MTDs) of CC-220 as monotherapy (MonoT) and in combination with dexamethasone (DEX) (DoubleT) in subjects with relapsed and refractory multiple myeloma (RRMM)
    1. To evaluate the safety of CC-220 as MonoT and DoubleT in subjects with RRMM
    2. To estimate the preliminary efficacy of CC-220 as MonoT and DoubleT in subjects with RRMM
    3. To evaluate the pharmacokinetics of CC-220 in subjects with RRMM
  • Locations


    Karmanos Cancer Institute - Detroit Headquarters

    4100 John R
    Detroit, MI 48201
    Get Directions
    Phone: 800-527-6266

    Karmanos Cancer Institute at Lawrence and Idell Weisberg Cancer Treatment Center - Farmington Hills

    31995 Northwestern Hwy
    Farmington Hills, MI 48334
    Get Directions
    Phone: 800-527-6266